← Leaderboards
Kelly Diringer Getz
University Of Pennsylvania
$4,068,250
Attributed
$5,128,374
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,128,374 · 3
By mechanism
R01$4,412,010 · 2
K01$716,364 · 1
Top collaborators
- Richard Aplenc3 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Stephen G Emerson$28,932,839
- Richard Aplenc$9,248,721
- Gary Weissman$3,005,893
- Regine Choe$2,957,811
- Yong Fan$9,585,740
Others in their field
Other Emerging Leaders on “Heart Function”
- Bradley G Hammill · Duke University$15,773,864
- Claudia L Satizabal · Boston University Medical Campus$12,021,427
- Angelo A. Cardoso · Beckman Research Institute/City Of Hope$10,820,438
- Julie Stoner · University Of Oklahoma Hlth Sciences Ctr$10,688,281
- Bing Yu · University Of Tx Md Anderson Can Ctr$10,034,200
- Barbara Halina Braffett · George Washington University$9,972,097
Research focus
Heart FunctionCohortPhenotypeVentricularTreatment OutcomeImproved OutcomeAcute Myelocytic LeukemiaLeftPediatric Oncology GroupMyocardial DysfunctionToxic EffectRecoveryChildhoodChildhood Acute Myeloid LeukemiaCardiomyopathiesCardiotoxicityFunctional DisorderHeart FailureMediatingClinical Trials Cooperative GroupChemotherapyEchocardiographyLeukemia TreatmentChild
Grant awards (12)
Predicting and Monitoring for Cardiac Toxicity in Pediatric AML$678,486
R01 · FY2025 · HL
Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications$329,736
R01 · FY2025 · HL · contact PI
Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications$676,727
R01 · FY2024 · HL · contact PI
Predicting and Monitoring for Cardiac Toxicity in Pediatric AML$622,359
R01 · FY2024 · HL
Predicting and Monitoring for Cardiac Toxicity in Pediatric AML$819,404
R01 · FY2023 · HL
Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications$746,751
R01 · FY2023 · HL · contact PI
Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications$538,547
R01 · FY2022 · HL · contact PI
Early Treatment-Related Cardiotoxicity and Subsequent Outcomes in Pediatric Acute Myeloid Leukemia: an Assessment of Development, Progression and Mitigation$142,992
K01 · FY2022 · HL · contact PI
Early Treatment-Related Cardiotoxicity and Subsequent Outcomes in Pediatric Acute Myeloid Leukemia: an Assessment of Development, Progression and Mitigation$141,372
K01 · FY2021 · HL · contact PI
Early Treatment-Related Cardiotoxicity and Subsequent Outcomes in Pediatric Acute Myeloid Leukemia: an Assessment of Development, Progression and Mitigation$144,288
K01 · FY2020 · HL · contact PI
Early Treatment-Related Cardiotoxicity and Subsequent Outcomes in Pediatric Acute Myeloid Leukemia: an Assessment of Development, Progression and Mitigation$145,152
K01 · FY2019 · HL · contact PI
Early Treatment-Related Cardiotoxicity and Subsequent Outcomes in Pediatric Acute Myeloid Leukemia: an Assessment of Development, Progression and Mitigation$142,560
K01 · FY2018 · HL · contact PI